Atsena Therapeutics

👁️ August is National Eye Exam Month! At Atsena Therapeutics, we're pioneering #GeneTherapy solutions for #InheritedRetinalDiseases, but we also believe in the importance of proactive eye health for everyone. Regular eye exams are crucial for detecting early signs of eye conditions that could affect your vision long-term. Whether managing an existing condition or simply safeguarding sight, an annual eye exam is a vital step. Join us in prioritizing eye health this month.   Image description: On the left side, there is a circular photo of an eye examination device. The photo is framed by three curved lines in orange, blue, and light blue, which partially encircle the image. On the right side, the text reads: August is National Eye Exam Month. At the bottom right corner, the Atsena Therapeutics logo is displayed. The background transitions from purple at the top to a gradient blue towards the bottom.

The FDA has granted rare pediatric disease (RPD) designation for Atsena Therapeutics gene therapy pruduct candidate ATSN-201, which is being examined to treat X-linked retinoschisis (XLRS): https://bit.ly/3yEbfsi

Atsena Therapeutics has received Rare Pediatric Disease designation (RPD) from the FDA for ATSN-201, its investigational gene therapy candidate, to treat X-linked retinoschisis (XLRS). Learn more on Glance: https://lnkd.in/erV7Pzdc #GlanceNews Patrick Ritschel

The #FDA granted rare pediatric disease designation to ATSN-201, a #genetherapy candidate for the treatment of X-linked retinoschisis. Healio spoke with Patrick Ritschel, CEO of Atsena Therapeutics, about the details 👇 #OcularSurgeryNews #Ophthalmology #Retina https://lnkd.in/e42FCKZx

We’re excited to share that Atsena was granted Rare Pediatric Disease (RPD) designation by the U.S. FDA for our #ocular #GeneTherapy candidate, ATSN-201, designed to treat X-linked Retinoschisis (#XLRS). This is Atsena’s second RPD designation this year and highlights the potential of our technology to address significant unmet needs for patients with #InheritedRetinalDiseases. With this designation, ATSN-201 will be eligible to receive a priority review voucher (#PRV) upon approval.   Currently, there are no approved treatments for XLRS, which primarily affects males and is typically diagnosed in early childhood. Read more here: https://lnkd.in/epHwbvTv   Image description:  The graphic is designed with a purple-to-blue gradient background and includes a picture of Atsena CEO Patrick Ritschel on the left side of the image. On the right side of the image, there is a quote from Mr. Ritschel that reads, “We are pleased to receive the FDA’s Rare Pediatric Disease designation for ATSN-201, which also marks the second RPD designation granted to Atsena this year. Having both of ourclinical-stage, ocular gene therapies receive this designation underscores the potential of our technology to address significant unmet needs for patients with inherited retinal diseases.” At the bottom right corner, the Atsena Therapeutics logo is displayed.

We’re excited to be included in this in-depth Retina Today article that highlights the promising advancements in the #InheritedRetinalDisease #genetherapy pipeline. This comprehensive overview sheds light on the innovative therapies being developed and features Atsena's groundbreaking work in this field.   As we continue to push the boundaries of what's possible in gene therapy, it's inspiring to see our efforts recognized alongside other leaders in the field as we continue to advance our potential best-in-class treatments for inherited retinal diseases in the clinic.   🔗 Read the full article here: https://lnkd.in/e7KkqT2i  

X-linked retinoschisis (#XLRS) is an #InheritedRetinalDisease (IRD) that is often diagnosed in childhood. Approximately 30,000 males in the U.S. and EU have XLRS, for which there are no approved treatments.    To learn more about living with XLRS, we spoke with patient Brendon Cavainolo and IRD specialist & vitreoretinal surgeon, Christine Kay, MD. Check out the video here: https://lnkd.in/grzEZVMt   Brendon and other patients with #VisionLoss drive our passion and commitment to developing innovative #GeneTherapies for IRDs.      Image description:   In the top left corner, the Atsena Therapeutics logo is displayed. The text reads, "See Brendon’s Story About Living with XLRS.” There are three images of patient Brendon Cavainolo interacting with IRD specialist & vitreoretinal surgeon, Christine Kay, MD. The largest image, centered on a laptop screen, shows Brendon undergoing an eye examination with Dr. Kay using specialized equipment. To the left, on a smartphone screen, Dr. Kay is speaking. To the right, on a tablet screen, Brendon is sitting and speaking in a home setting.

We’re excited to welcome Joe Zakrzewski as the Chair of our #BoardOfDirectors. A 30-year biotech and pharma veteran, we look forward to leveraging Joe’s expertise and insights as we continue to advance the clinical development of our investigational #GeneTherapies for #InheritedRetinalDiseases.   Read more in our press release: https://lnkd.in/eagg7tES   Image description: A picture of Mr. Zakrzewski is on the left. Text on the right reads “Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair.” The Atsena Therapeutics logo is in the bottom right corner.

VISIONS 2024, the global conference of the Foundation Fighting Blindness, brought together individuals and families from all over the world who are affected by blinding diseases. Kenji Fujita, our Chief Medical Officer, and Kara Fick, our Director of Patient Advocacy and Medical Affairs, had the pleasure of attending VISIONS to engage with the #LowVision community and meet inspiring families. It was an honor to be part of an event that closely aligns with Atsena’s mission to improve the quality of life of patients with #InheritedRetinalDisease. Image description: Text on the top reads “Atsena at Foundation Fighting Blindness VISIONS ’24.” On the left, Kara Fick and Kenji Fujita are standing at Atsena’s booth. In the middle, a sign at the conference details the session in which Kenji Fujita spoke, “Concurrent Science Session: Gene Therapy and Genome Editing.” On the right, Kenji Fujita is speaking into a microphone. The Atsena Therapeutics logo is in the bottom right corner. 

Our Chief Medical Officer Kenji Fujita, MD, had the pleasure of speaking with Tyler Menichiello about the rise of gene therapies being developed for #InheritedRetinalDiseases and Atsena’s clinical programs in #LCA1 and #XLRS. Check out the article in Cell & Gene. ⬇ #GeneTherapy #ophthalmology